U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

Date of Report (Date of earliest event reported): November 18, 2016

HH BIOTECHNOLOGY HOLDINGS COMPANY

(Exact name of registrant as specified in its charter)

0-23015

(Commission File No.)

Nevada

(State or other jurisdiction of

incorporation or organization)

87-0450232

(IRS Employer Identification No.)

C Site 25-26F President Building, No. 69 Heping North Street

Heping District, Shenyang 110003, Peoples Republic of China

(Address of principal executive offices)

0086-24-22813888

(Registrant’s telephone number)

Not applicable

(Former Name or Former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 18, 2016, the Board of Directors of HH Biotechnology Holdings Company (the “Company”) adopted resolutions increasing the number of directors on the board to five and electing Mr. Charles T. Mathews as a director to fill the new directorship, and Mr. Mathews was assigned as the chairman of the Compensation Committees of the Board of Directors of the Company.

For service on the Board, Mr. Mathews will receive a quarterly fee of $10,000 and reimbursement of expenses.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	HH Biotechnology Holdings Company

Date: November 21, 2016	By:	/s/ Sheng Jiang
		Sheng Jiang
		Chief Executive Officer

HH BIOTECHNOLOGY HOLDINGS CO 8-K